MicroRNA-138 Regulates T-Cell Function by Targeting PD-1 in Patients with Hepatitis B Virus-Related Liver Diseases.

OBJECTIVE T-cell exhaustion in hepatitis B virus (HBV) infection, which results from upregulation of programmed cell death-1 (PD-1), leads to persistent HBV infection and related disease progression. Therefore, agents targeting PD-1 may prove beneficial in the treatment of this condition. MicroRNA-138 (miR-138) possesses an anti-tumor ability in that it targets immune checkpoints, including PD-1. However, the function and underlying mechanisms of miR-138 in patients with HBV infection remains unclear. METHODS Specimens were collected from healthy volunteers (n = 43) and patients with chronic hepatitis B (CHB; n = 52), liver cirrhosis (LC; n = 26), and hepatocellular carcinoma (HCC; n = 31); carriers of HBV who were asymptomatic (n = 51); and patients with CHB receiving antivirus treatment (n = 11). These specimens were then used to study the expression and relationship among miR-138, PD-1, and HBV DNA viral load. To investigate the role of miR-138 in regulating PD-1 expression and determine the effect of miR-138 in regulating T-cell function, a luciferase assay and a transfection assay were each performed with primary CD3+ T cells. RESULTS We found that PD-1 was upregulated and miR-138 was downregulated in patients with CHB, LC, and HCC. Correlations analysis revealed that PD-1 expression was positively correlated with HBV DNA viral load whereas miR-138 was negatively correlated. Luciferase assay results showed that miR-138 directly inhibited PD-1 expression by interacting with the 3'-untranslated region of PD-1. As a result of miR-138 overexpression in primary T cells, PD-1 in these T cells was downregulated and antivirus cytokines secreted by T cells were significantly upregulated. In addition, the expression levels of PD-1 and miR-138 were reversed in patients with CHB who received antivirus treatments. CONCLUSION Results showed that miR-138 can promote T-cell responses within patients with HBV infection by inducing a PD-1 blockade. Such an effect suggests that miR-138 may serve as a new therapeutic target for the treatment of HBV infection.

[1]  Arash Salmaninejad,et al.  PD-1 and cancer: molecular mechanisms and polymorphisms , 2018, Immunogenetics.

[2]  A. Gehring.  New treatments to reach functional cure: Rationale and challenges for emerging immune-based therapies. , 2017, Best practice & research. Clinical gastroenterology.

[3]  M. Dandri,et al.  The Role of cccDNA in HBV Maintenance , 2017, Viruses.

[4]  Jianxun Song,et al.  Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies , 2017, Front. Immunol..

[5]  A. Tramontano,et al.  Genome-wide identification of direct HBx genomic targets , 2017, BMC Genomics.

[6]  Andreia J. Amaral,et al.  miRNA profiling of human naive CD4 T cells links miR‐34c‐5p to cell activation and HIV replication , 2017, The EMBO journal.

[7]  Ronald D. Vale,et al.  T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition , 2016, Science.

[8]  F. Piva,et al.  The choice of endogenous controls in exosomal microRNA assessments from biofluids , 2016, Tumor Biology.

[9]  M. Gilbert,et al.  MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. , 2016, Neuro-oncology.

[10]  A. Bertoletti,et al.  Adaptive immunity in HBV infection. , 2016, Journal of hepatology.

[11]  T. Diekwisch,et al.  MicroRNA-138 Inhibits Periodontal Progenitor Differentiation under Inflammatory Conditions , 2016, Journal of dental research.

[12]  A. Dickinson,et al.  Evaluation of optimal extracellular vesicle small RNA isolation and qRT-PCR normalisation for serum and urine. , 2016, Journal of immunological methods.

[13]  Gérard Krause,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[14]  X. Zang,et al.  New immunotherapies targeting the PD-1 pathway. , 2015, Trends in pharmacological sciences.

[15]  Zheng Zhang,et al.  Regulation of T cell function by microRNA-720 , 2015, Scientific Reports.

[16]  Qianqian Zhu,et al.  microRNA-4717 differentially interacts with its polymorphic target in the PD1 3′ untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases , 2015, Oncotarget.

[17]  B. Kroesen,et al.  Immuno‐miRs: critical regulators of T‐cell development, function and ageing , 2015, Immunology.

[18]  Hui Zhang,et al.  BTLA exhibits immune memory for αβ T cells in patients with active pulmonary tuberculosis. , 2014, American journal of translational research.

[19]  Hong Wu,et al.  MicroRNAs Associated With HBV Infection And HBV-related HCC , 2014, Theranostics.

[20]  X. Chen,et al.  Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth , 2014, Cell Research.

[21]  K. Chao,et al.  MicroRNA‐138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF‐1α , 2013, International journal of cancer.

[22]  P. Ye,et al.  MicroRNAs may solve the mystery of chronic hepatitis B virus infection. , 2013, World journal of gastroenterology.

[23]  W. Gerlich.  Medical Virology of Hepatitis B: how it began and where we are now , 2013, Virology Journal.

[24]  Hao Ren,et al.  Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma. , 2012, World journal of gastroenterology.

[25]  N. Seki,et al.  Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma , 2012, International journal of oncology.

[26]  Takashi Saito,et al.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 , 2012, The Journal of experimental medicine.

[27]  A. Bertoletti,et al.  Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. , 2011, Journal of hepatology.

[28]  M. Maini,et al.  Role of the coinhibitory receptor cytotoxic T lymphocyte antigen‐4 on apoptosis‐Prone CD8 T cells in persistent hepatitis B virus infection , 2011, Hepatology.

[29]  Lu Jiang,et al.  MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. , 2009, Cancer letters.

[30]  Roger Williams,et al.  CD8+ T Cell Control of Hepatitis B Virus Replication: Direct Comparison between Cytolytic and Noncytolytic Functions , 2009, The Journal of Immunology.

[31]  Pratip K. Chattopadhyay,et al.  The Size of the Viral Inoculum Contributes to the Outcome of Hepatitis B Virus Infection , 2009, Journal of Virology.

[32]  G. Wakabayashi,et al.  Downregulation of miR‐138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines , 2008, Cancer science.

[33]  Zhi Chen,et al.  PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. , 2008, Molecular immunology.

[34]  R. Koup,et al.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection , 2006, The Journal of experimental medicine.

[35]  A Valli,et al.  Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. , 1990, Journal of immunology.